Regeneron Pharmaceuticals Inc (REGN) Stock Rating

Regeneron Pharmaceuticals discovers, develops, and commercializes treatments for eye disease, cardiovascular disease, cancer, and inflammation. Its marketed products include low-dose Eylea and Eylea HD for wet age-related macular degeneration and other eye diseases, Dupixent in immunology, Praluent for lowering LDL cholesterol, Libtayo in oncology, Kevzara for rheumatoid arthritis, and Lynozyfic for multiple myeloma. Its largest collaboration partners are Sanofi (Dupixent and others) and Bayer (Eylea).

Rating as of 2026-07-07. Live price updates in real time.